Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and fluid replacement; dextrose provides caloric support.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Fluid and electrolyte replenishment,Correction of metabolic acidosis,Intravenous source of calories
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable; components are endogenous substances. Dextrose has a plasma half-life of approximately 1.5-2.5 hours in normal glucose metabolism; electrolytes have half-lives dependent on renal function (e.g., sodium half-life ~1-2 days).
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are absorbed and excreted by the kidneys.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Renal excretion of water and electrolytes; dextrose is metabolized to CO2 and water. >90% of water and electrolytes are excreted renally; dextrose is fully metabolized.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Minimal (<5%); electrolytes are not significantly protein-bound; dextrose does not bind to proteins.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Electrolytes distribute to total body water (~0.6 L/kg); dextrose distributes to extracellular fluid initially (~0.2 L/kg) then intracellularly.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% bioavailability.
Intravenous: 100%.
No specific dose adjustment; monitor fluid and electrolyte status closely in renal impairment due to risk of volume overload and electrolyte disturbances.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances due to potential altered metabolism.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Intravenous infusion; rate based on weight: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, and 20 m L/kg/day for each kg above 20 kg.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Use with caution; consider lower infusion rates due to decreased renal function and risk of fluid overload; monitor electrolytes and renal function closely.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
Not for use in patients with hyperglycemia or certain electrolyte imbalances; solutions containing aluminum may be toxic with prolonged use in renally impaired patients.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Monitor serum electrolytes, fluid balance, blood glucose; risk of hyperglycemia, hypokalemia, fluid overload; avoid in patients with renal impairment or heart failure.
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hyperkalemia, hypernatremia, hyperglycemia, severe metabolic acidosis, anuria, or hypersensitivity to any component.
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No direct food interactions. However, dietary intake of electrolytes (e.g., potassium, sodium) should be considered in patients receiving this solution. Avoid high-potassium foods if hyperkalemia is a concern.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/third trimester: use as needed for fluid/electrolyte balance. Dextrose may cause maternal hyperglycemia, which can affect fetal glucose and insulin levels, potentially leading to fetal hyperinsulinism and neonatal hypoglycemia if maternal glucose is poorly controlled.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Isolyte R in Dextrose 5% components (dextrose, electrolytes) are normal constituents of breast milk. No known adverse effects. M/P ratio not applicable as dextrose and electrolytes are endogenous substances. Use is considered compatible with breastfeeding.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
No specific dose adjustments required for pregnancy. However, due to increased plasma volume and glomerular filtration rate in pregnancy, individualize based on fluid and electrolyte needs. Monitor for hyperglycemia, which may require dose reduction or insulin therapy. Use caution in preeclampsia or impaired renal function.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
ISOLYTE R in Dextrose 5% is an isotonic solution used for fluid and electrolyte replacement. Monitor serum glucose and electrolytes, especially in diabetic patients. Avoid in patients with hyperglycemia, hyperkalemia, or hyperlactatemia. Use with caution in renal impairment. The solution contains 130 m Eq/L sodium, 4 m Eq/L potassium, 3 m Eq/L calcium, 1 m Eq/L magnesium, 109 m Eq/L chloride, 28 m Eq/L lactate, and 5% dextrose. It provides 170 kcal/L. Do not administer simultaneously with blood products through same line.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
Inform your healthcare provider if you have diabetes, kidney problems, or heart failure.,Report any signs of fluid overload (swelling, difficulty breathing) or electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,This solution contains sugar; monitor blood glucose if you have diabetes.,Do not use if the solution is cloudy or contains particles.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Electrolyte and fluid replacement; dextrose provides caloric support.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/th. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.